Preventative Treatment of Alzheimer’s Disease (AD)NEUROSTEM®
NEUROSTEM® is under-development for the treatment of Alzheimer’s
disease, which is based on the Allogeneic Umbilical Cord Blood-derived
Mesenchymal Stem Cell drug.
Currently, Phase 1/2a clinical trial of Ministry of Food & Drug Safety is ongoing and preparing for the clinical trial (FDA) in the U.S.
10 Days After
Accumulation of β-amyloid, which causes Alzheimer-type dementia, induces learning and memorizing disorders by damaging nerve cells.
Once NEUROSTEM® is administrated to the patient’s brain with Alzheimer-type dementia, the protein secreted from umbilical cord blood-derived mesenchymal stem cells promotes degradation of β-amyloid by triggering secretion of β-amyloid degrading enzyme (usually secreted by microglia).